Host-targeted Approaches
for Prevention and treatment
of Hospital-Acquired
Pneumonia
News & events
HAP² project
“HAP2” is a 5-year project involving 10 partners from 6 countries, which aims to develop host-directed drugs and biomarkers to enhance the prevention and treatment of hospital-acquired pneumonia (HAP): an infectious disease of major concern for Europe, and develop precision medicine in infectious diseases.
HAP?
HAP is defined as a respiratory tract infection that occurs 48 hours or more after hospital admission. It is the most frequent cause of hospital-acquired infections and the main cause of antibiotics consumption in European hospitals.
5 years
2020 > 2024
600
Patients
10
Partners
6
Countries
Funding :
9 996 350€
Partners
